A- A A+

Frankfurt/Main. Was Corona für Drogenabhängige bedeutet 

Zu den Menschen, die durch die Coronakrise in große Not geraten sind, gehören auch Drogenabhängige. Dr. Marion Friers vom Eastside, Europas größter niedrigschwelliger Drogenhilfeeinrichtung in Frankfurt, schildert die schwierige Situation nach mehr als einem Jahr Pandemie. (Medical Tribune, 10.07.2021)

https://www.medical-tribune.de/medizin-und-forschung/artikel/was-corona-fuer-drogenabhaengige-bedeutet/

Psychological Distress and Tobacco Use Among Hospital Workers During COVID-19. 

Mounir I, Menvielle L, Perlaza S, Chênevert D, Planchard JH, Fabre R, Benoit M, Benyamina A, Rolland B, Cherikh F, David R. 

Front Psychiatry. 2021 Jul 28;12:701810. doi: 10.3389/fpsyt.2021.701810. PMID: 34393861; PMCID: PMC8355418.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8355418/

Substances use between early and later stages of the COVID-19 pandemic in Israel. 

Bonny-Noach H, Cohen-Louck K, Levy I. 

Isr J Health Policy Res. 2021 Aug 12;10(1):46. doi: 10.1186/s13584-021-00484-8. PMID: 34384483; PMCID: PMC8359629.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8359629/

Accidental deaths from hand sanitizer consumption among persons with alcohol dependence during the COVID-19 lockdown in India: Analysis of media reports. 

Khadse PA, Murthy P. 

Asian J Psychiatr. 2021 Sep;63:102794. doi: 10.1016/j.ajp.2021.102794. Epub 2021 Jul 26. PMID: 34352511; PMCID: PMC8312056.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8312056/

Opioid overdose crises during the COVID-19 pandemic: implication of health disparities. 

Patel I, Walter LA, Li L.

Harm Reduct J. 2021 Aug 16;18(1):89. doi: 10.1186/s12954-021-00534-z. PMID: 34399771; PMCID: PMC8365290.

https://harmreductionjournal.biomedcentral.com/articles/10.1186/s12954-021-00534-z

Mental Health and COVID-19: Challenges and Multimodal Clinical Solutions. 

Masand P, Patkar A, Tew C, Hoerner A, Szabo ST, Gupta S. 

J Psychiatr Pract. 2021 Jul 28;27(4):254-264. doi: 10.1097/PRA.0000000000000560. PMID: 34398575; PMCID: PMC8318386.

https://europepmc.org/article/pmc/pmc8318386#free-full-text

Understanding the Impacts of Novel Coronavirus Outbreaks on People Who Use Drugs: A Systematic Review to Inform Practice and Drug Policy Responses to COVID-19. 

Munro A, Booth H, Gray NM, Love J, Mohan ARM, Tang J, MacGillivray S. 

International Journal of Environmental Research and Public Health. 2021; 18(16):8470. doi.org/10.3390/ijerph18168470 

https://www.mdpi.com/1660-4601/18/16/8470/htm

„Superspreading Events“ als Treiber der Evolution von SARS-CoV-2

Wie verlief die Evolution des SARS-CoV-2 seit dem Beginn der Pandemie? Wissenschaftler aus dem Deutschen Krebsforschungszentrum und vom Applied Biomedical Science Institute, San Diego, USA, analysierten dies für die US-Bevölkerung an den Daten der nationalen US-amerikanischen SARS-CoV-2 Sequenzdatenbank. Die Kombination von Mutationen plus „Super Spreading Events“ befeuert die Verbreitung genetischer Virusvarianten in der Bevölkerung. (Deutsches Krebsforschungszentrum, 18.08.2021)

https://idw-online.de/de/news774385

COVID-19 Vaccine FAQs

Your answers to commonly asked questions regarding the COVID-19 vaccine. (Addiction Policy Forum, USA, 17.08.2021)

https://www.addictionpolicy.org/post/covid-19-vaccine-faqs

Patient-Centered Telehealth Solution for Observed Urine Collections in Substance Use Disorder Care Delivery During COVID-19 and Beyond. 

Brett A, Foster H, Joseph M, Warrington JS. 

J Patient Exp. 2021 Jul 29;8:23743735211033128. doi: 10.1177/23743735211033128. PMID: 34377769; PMCID: PMC8330461.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8330461/

Challenges in delivering telemedicine to vulnerable populations: experiences of an addiction medical service during COVID-19. 

Hew A, Arunogiri S, Lubman DI. 

Med J Aust. 2021 Aug 7. doi: 10.5694/mja2.51213. Epub ahead of print. PMID: 34365643.

https://onlinelibrary.wiley.com/doi/10.5694/mja2.51213

Prioritizing COVID-19 vaccination for people with addictive disorders. 

Trujols J, Cadafalch J, Alvarado PJ, Duran-Sindreu S. 

Adicciones. 2021 Jul 1;33(3):285-286. English, Spanish. doi: 10.20882/adicciones.1686. PMID: 34171116.

https://adicciones.es/index.php/adicciones/article/view/1686

COVID-19 Pandemic Impact on Substance Misuse: A Social Media Listening, Mixed Method Analysis. 

Arillotta D, Guirguis A, Corkery JM, Scherbaum N, Schifano F. 

Brain Sci. 2021 Jul 9;11(7):907. doi: 10.3390/brainsci11070907. PMID: 34356142; PMCID: PMC8303488.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8303488/

Vulnerability of personality disorder during COVID-19 crises: a multicenter survey of mental and social distress among patients referred to treatment. 

Hartveit Kvarstein E, Zahl KE, Stänicke LI, Pettersen MS, Baltzersen ÅL, Johansen MS, Eikenæs IU, Hummelen B, Wilberg T, Ajo Arnevik E, Pedersen G. 

Nord J Psychiatry. 2021 Aug 9:1-12. doi: 10.1080/08039488.2021.1942980. Epub ahead of print. PMID: 34369842.

https://www.tandfonline.com/doi/full/10.1080/08039488.2021.1942980

Factors of Negative Affect in Elderly Patients With Substance Use Disorders During COVID-19 Pandemic. 

Wang Q, Wang Y, Zuo J, Zhou Y, Yang WFZ, Liao Y, Tang J, Wang X, Yang Q, Wu Q, Wu HE, Goodman CB, Liu T, Zhang X. 

Front Psychiatry. 2021 Jul 20;12:697472. doi: 10.3389/fpsyt.2021.697472. PMID: 34354617; PMCID: PMC8329338.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8329338/

A qualitative study on overdose response in the era of COVID-19 and beyond: how to spot someone so they never have to use alone. 

Perri M, Kaminski N, Bonn M, Kolla G, Guta A, Bayoumi AM, Challacombe L, Gagnon M, Touesnard N, McDougall P, Strike C. 

Harm Reduct J. 2021 Aug 5;18(1):85. doi: 10.1186/s12954-021-00530-3. PMID: 34353323; PMCID: PMC8339679.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8339679/

Homeless and COVID-19: Interventions for an Acute Exacerbation of a Chronic Condition. 

Rottnek F, Laxton A. 

Mo Med. 2021 May-Jun;118(3):196-202. PMID: 34149073; PMCID: PMC8210986.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8210986/

Association Between Mental Health Disorders and Mortality Among Patients With COVID-19 in 7 Countries: A Systematic Review and Meta-analysis. 

Fond G, Nemani K, Etchecopar-Etchart D, Loundou A, Goff DC, Lee SW, Lancon C, Auquier P, Baumstarck K, Llorca PM, Yon DK, Boyer L. 

JAMA Psychiatry. 2021 Jul 27:e212274. doi: 10.1001/jamapsychiatry.2021.2274. Epub ahead of print. PMID: 34313711; PMCID: PMC8317055.

https://jamanetwork.com/journals/jamapsychiatry/fullarticle/2782457

RKI-Berechnung: Impfkampagne hat mehr als 38.000 Todesfälle verhindert

Berlin – Die Impfkampagne gegen das Coronavirus SARS-CoV-2 hat laut einer Modellrechnung des Ro­bert-Koch-Instituts (RKI) in Deutschland geschätzt Tausende Todesfälle verhindert. „Unsere hier präsen­tierten Daten belegen den überragenden Nutzen der COVID-19-Impfung bereits in den ersten 6,5 Mona­ten der Impfkam­pagne in Deutschland 2021“, schreiben die Autoren der Analyse. (aerzteblatt.de, 09.08.2021)

https://www.aerzteblatt.de/nachrichten/126222/RKI-Berechnung-Impfkampagne-hat-mehr-als-38-000-Todesfaelle-verhindert

USA. Substance Use Issues Are Worsening Alongside Access to Care 

Amid the crisis of the COVID-19 pandemic, the United States is also facing a worsening substance use crisis. More than one in ten adults have reported starting or increasing the use of alcohol or drugs to cope with the pandemic. Additionally, deaths due to drug overdose spiked during the pandemic, primarily driven by opioids. Recently released data shows that over 93,000 drug overdose deaths were reported in 2020 – the highest on record and nearly a 30% increase from 2019 (Figure 1). (Kaiser Family Foundation, 12.08.2021)

https://www.kff.org/policy-watch/substance-use-issues-are-worsening-alongside-access-to-care

Living Under Coronavirus and Injecting Drugs in Bristol (LUCID-B): A qualitative study of experiences of COVID-19 among people who inject drugs

Kesten, J. M., Holland, A., Linton, M. J., Family, H., Scott, J., Horwood, J., Hickman, M., Telfer, M., Ayres, R., Hussey, D., Wilkinson, J. & Hines, L. A.,

31 Dec 2021, International Journal of Drug Policy. 98, 103391.

https://www.sciencedirect.com/science/article/pii/S0955395921002966

Developing a digital health strategy for people who use drugs: Lessons from COVID-19. 

Perri M, Guta A, Gagnon M, Bonn M, Leece P, Bayoumi AM, Rai N, Touesnard N, Strike C. 

Digit Health. 2021 Jun 28;7:20552076211028404. doi: 10.1177/20552076211028404. PMID: 34262782; PMCID: PMC8243112.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8243112/

An examination of telehealth policy impacts on initial rural opioid use disorder treatment patterns during the COVID-19 pandemic. 

Hughes PM, Verrastro G, Fusco CW, Wilson CG, Ostrach B. 

J Rural Health. 2021 Jun;37(3):467-472. doi: 10.1111/jrh.12570. Epub 2021 Mar 15. PMID: 33720447; PMCID: PMC8250742.

https://onlinelibrary.wiley.com/doi/10.1111/jrh.12570

Impact of the Coronavirus Pandemic on Substance Use Disorder Treatment: Findings from a Survey of Specialty Providers in California. 

Henretty K, Padwa H, Treiman K, Gilbert M, Mark TL. 

Subst Abuse. 2021 Jul 6;15:11782218211028655. doi: 10.1177/11782218211028655. PMID: 34285496; PMCID: PMC8264730.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8264730/

USA. How COVID pandemic changed methadone treatment for addiction

Here’s one more lesson from the COVID-19 pandemic: It appears safe to relax restrictions on methadone, the oldest and most stigmatized treatment drug for opioid addiction. (AP, 12.08.2021)

https://apnews.com/article/science-health-pandemics-coronavirus-pandemic-c36442b3fe8f2074e2fe3907d11ca579

Continuing increased access to buprenorphine in the United States via telemedicine after COVID-19. 

Davis CS, Samuels EA. 

Int J Drug Policy. 2021 Jul;93:102905. doi: 10.1016/j.drugpo.2020.102905. Epub 2020 Aug 15. PMID: 32811685; PMCID: PMC7428767.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7428767/

Methadone Access for Opioid Use Disorder During the COVID-19 Pandemic Within the United States and Canada. 

Joudrey PJ, Adams ZM, Bach P, Van Buren S, Chaiton JA, Ehrenfeld L, Guerra ME, Gleeson B, Kimmel SD, Medley A, Mekideche W, Paquet M, Sung M, Wang M, You Kheang ROO, Zhang J, Wang EA, Edelman EJ. 

JAMA Netw Open. 2021 Jul 1;4(7):e2118223. doi: 10.1001/jamanetworkopen.2021.18223. PMID: 34297070.

https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2782211

Opioid use disorder treatment disruptions during the early COVID-19 pandemic and other emergent disasters: a scoping review addressing dual public health emergencies. 

Henderson R, McInnes A, Mackey L, Bruised Head M, Crowshoe L, Hann J, Hayward J, Holroyd BR, Lang E, Larson B, Leonard AJ, Persaud S, Raghavji K, Sarin C, Virani H, Wadsworth IW, Whitman S, McLane P. 

BMC Public Health. 2021 Jul 28;21(1):1471. doi: 10.1186/s12889-021-11495-0. PMID: 34320954; PMCID: PMC8318046.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8318046/

Experiences of people with opioid use disorder during the COVID-19 pandemic: A qualitative study. 

Galarneau LR, Hilburt J, O’Neill ZR, Buxton JA, Scheuermeyer FX, Dong K, et al. (2021) 

PLoS ONE 16(7): e0255396. doi.org/10.1371/journal.pone.0255396

https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0255396

USA. Pandemic-based approach to methadone treatment restrictions should remain

When the COVID-19 pandemic ripped through New England and the rest of the United States in early 2020, substance use disorder treatment centers were forced to make massive changes to minimize the spread of coronavirus. 

The fear of COVID-19 spread into crowded treatment programs run by the national Substance Abuse and Mental Health Services Administration, prompting them to relax stringent federal regulations on distributing methadone, a common treatment for opioid use. The agency allowed programs to increase the number of take-home methadone doses that patients could receive and reduce the frequency of counseling and drug testing—changes that sparked concerns over medication diversion and lapses in treatment. 

But a new study by researchers at the Yale School of Public Health finds that these concerns appear unfounded. Relaxing the requirements for dispensing take-home methadone treatments did not significantly lead to an increase in fatal methadone-related overdoses in Connecticut at all, they found. The changes also did not result in reductions in the number of patients receiving treatment for their opioid use disorder.

Furthermore, the findings suggest that the changes to the restrictions on methadone implemented during the pandemic should continue indefinitely to improve access to the drug, the researchers wrote. (MedicalXpress, USA, 21.07.2021)

https://medicalxpress.com/news/2021-07-pandemic-based-approach-methadone-treatment-restrictions.html